U.S. Department of Justice Reclassifies Medical Marijuana to Schedule III

This reclassification aligns federal policy with state legalizations, potentially unlocking a $47 billion market while easing regulatory burdens.

• On April 23, 2026, the U.S. Department of Justice reclassified state-regulated medical marijuana and FDA-approved products from Schedule I to Schedule III.
• Acting Attorney General Todd Blanche announced this change, fulfilling President Trump's December 2025 executive order aimed at loosening federal restrictions.
• The reclassification acknowledges lower abuse potential, facilitating research and easing tax burdens, but does not legalize recreational marijuana federally.

• Marijuana has been classified as Schedule I since 1970, indicating high abuse potential and no accepted medical use, despite its medical legalization in 48 states.
• The Biden administration proposed rescheduling in 2024, but efforts stalled until Trump's executive order in December 2025 prompted the current reclassification.
• The cannabis industry is projected to reach $47 billion in sales in 2026, highlighting the economic significance of this policy shift.

The April 2026 reclassification of medical marijuana products to Schedule III marks a significant shift in U.S. drug policy, reflecting a growing recognition of the medical benefits of cannabis. This change is rooted in a broader societal and scientific consensus that has evolved over decades, challenging the long-standing classification that deemed marijuana as having no accepted medical use and a high potential for abuse.

The reclassification allows for a more nuanced approach to cannabis regulation, aligning federal law with the realities of state-level legalization. Currently, 48 states have legalized medical marijuana, and 24 states have approved recreational use. This disconnect between state and federal law has created a complex legal landscape, often hindering research and development in the cannabis sector. By moving marijuana to Schedule III, the DOJ acknowledges its lower abuse potential, akin to substances like ketamine and certain painkillers, which opens the door for more extensive research into its medical applications.

One of the most immediate impacts of this reclassification is the easing of tax burdens for cannabis businesses. Previously, Section 280E of the Internal Revenue Code imposed strict limitations on the deductions that cannabis businesses could take, effectively taxing them at a higher rate than other industries. With the new classification, businesses can expect relief from these burdens, allowing for reinvestment and growth in a rapidly expanding market.

Moreover, the reclassification improves banking access for cannabis companies, which have historically struggled to secure financial services due to federal prohibitions. This change could lead to increased investment in the sector, further driving innovation and expansion. However, it is crucial to note that while this reclassification is a step forward, it does not legalize recreational marijuana at the federal level, leaving a significant portion of the market still under restrictive regulations.

The broader rescheduling proceedings set to begin on June 29, 2026, will further explore the implications of cannabis use across all categories, including recreational use. This could lead to more comprehensive reforms in the future, but for now, the focus remains on medical applications and the economic opportunities they present.

• Cannabis businesses: Expect increased investment and reduced tax burdens, enhancing profitability.
• Researchers and medical professionals: Gain improved access to study cannabis's medical benefits, potentially leading to new treatments.
• Investors: Cannabis stocks may experience volatility as the market adjusts to the new regulatory landscape.
• State regulators: Face challenges in aligning state laws with federal changes, particularly regarding recreational use.

• Broader rescheduling proceedings on June 29, 2026: This will determine the future of cannabis regulation and could lead to further changes in how marijuana is classified and treated under federal law.
• Market reactions from cannabis stocks: Watch for fluctuations in stock prices of cannabis companies as they adapt to the new regulatory environment and investor sentiment shifts.
• State-level responses: Monitor how states adjust their regulations in light of federal changes, particularly those with existing recreational markets.